Tag Archives: clinical trials

Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer

This randomized, open label, phase III clinical trial (1988–1992) compared the efficacy and safety of a dose-dense regimen of single-agent cisplatin with a standard 3-weekly schedule in first-line chemotherapy for … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Harms often surface years after cancer drug approval

Serious and sometimes life-threatening side effects often go unreported until years after cancer drugs have been approved, Canadian researchers said Monday. Within four years of approval, five of the 12 … Continue reading 

Posted in News | Also tagged , | Leave a comment

Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer

Immunovaccine Inc. today announced that it will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer. The development plan was based on positive input from key opinion … Continue reading 

Posted in News | Also tagged , | Leave a comment

Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study

Paclitaxel is one of the most common antitumour agents paclitaxel for the treatment of primary and relapsed ovarian cancer. Based on a German multicentre observational study, this article reflects the … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

The perils of taking experimental cancer drugs

Trying a new, experimental cancer drug may offer a glimpse of hope for very sick patients, but often does more harm than good, a new study shows. Researchers said cancer … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Girls with ovarian germ-cell tumors can safely skip chemotherapy unless disease recurs, new study suggests

Researchers from Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

New White Paper Issued on Ovarian Cancer

The Society of Gynecologic Oncologists (SGO) has issued a comprehensive white paper — as part the organization’s professional Gynecologic Cancer Collaborative education program — that provides an overview of and … Continue reading 

Posted in News | Also tagged , , , , , , , , | Leave a comment

Avastin helps in ovarian cancer but effects fade

Roche’s blockbuster drug Avastin helps women with ovarian cancer live longer without their disease getting worse, but its effect peaks at 12 months and then diminishes, researchers said on Monday. … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Takeda drug shows some effect in ovarian cancer

An experimental ovarian cancer drug from Takeda (4502.T) helped some difficult-to-treat patients in a small mid-stage trial, underscoring the case for more research on the compound, researchers said on Saturday. … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Amgen drug extends survival in ovarian cancer study

* AMG 386 extends survival 1.6 mos vs chemotherapy alone * Amgen has launched Phase 3 trial LOS ANGELES Oct 9 (Reuters) – A mid-stage trial of an experimental drug … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor Alpha, in Epithelial Ovarian Cancer: A Phase I Study

Purpose: Folate receptor alpha (FRα) expression is highly restricted in normal adult tissues, but upregulated in a wide range of human cancer types including epithelial ovarian cancer (EOC). Farletuzumab, a … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer

Purpose One attempt to improve long-term survival in patients with advanced ovarian cancer was thought to be the addition of more non–cross-resistant drugs to platinum-paclitaxel combination regimens. Gemcitabine was among … Continue reading 

Posted in News | Also tagged | Leave a comment